Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has filed a prospectus supplement with the SEC for an At-The-Market (ATM) program to offer and sell up to $75 million in American Depositary Shares (ADS). The proceeds will support R&D and general corporate purposes. The company plans to issue up to 23,673,831 ADSs, potentially diluting shareholder value by approximately 26%. Qualified institutional buyers and accredited investors will be eligible for purchase. The program's effectiveness depends on market conditions and may be updated quarterly on the company’s website.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call on May 10, 2022, at 2 p.m. CEST to discuss its business progress in Q1 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Participants can join via webcast or telephone. Innate Pharma is dedicated to oncology innovations through therapeutic antibodies, aiming to enhance treatment outcomes for cancer patients. They have significant collaborations with top biotech firms, strengthening their pipeline against high unmet medical needs.
Innate Pharma announced the first patient dosing in the Phase 3 PACIFIC-9 trial for patients with unresectable Stage III non-small cell lung cancer (NSCLC). This trial evaluates the efficacy of durvalumab in combination with monalizumab or oleclumab. The initiation of the trial triggers a $50 million milestone payment from AstraZeneca to Innate, strengthening its cash position. The PACIFIC-9 study aims to assess whether these combinations improve treatment outcomes following standard platinum-based concurrent chemoradiation therapy.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host its Annual General Meeting (AGM) on May 20, 2022, at 10:30 a.m. CEST in Marseille, France. The AGM will be broadcasted live, and only registered shareholders can participate. Shareholders must register their shares at least two business days before the AGM. The Notice of Meeting published on April 8, 2022, includes the agenda and proposed resolutions. Documentation for the AGM is available on the Company’s website.
Innate Pharma announced the filing of its 2021 Universal Registration Document with the French market authority AMF and its annual report on Form 20-F with the SEC. Both filings cover the year ending December 31, 2021, and are accessible via the company's and regulatory websites. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment, supported by partnerships with major biopharmaceutical companies. The company is based in Marseille, France, and trades on Euronext Paris and Nasdaq under the ticker IPHA.
Innate Pharma reported a net loss of €52.8 million for 2021, showing an improvement from a €64.0 million loss in 2020. Revenue dropped 64.6% to €24.7 million, largely due to reduced collaboration revenue from AstraZeneca. The cash position stands at €159.7 million. Notable advancements include the initiation of a Phase 3 trial for monalizumab with AstraZeneca and promising data from the lacutamab study in mycosis fungoides. The company also highlighted progress in its ANKET platform with Sanofi's Phase 1 trial initiation. A conference call is scheduled for today to discuss these results.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call set for March 24, 2022, at 2 p.m. CET to discuss its financial results for the full year ending December 31, 2021. Key executives, including the CEO and CFO, will participate in the call. The event will be accessible via a live webcast and phone dial-in options. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system against cancer and maintains collaborations with major biopharmaceutical companies like AstraZeneca and Bristol-Myers Squibb.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced as of March 1, 2022, it has a total of 79,728,657 ordinary shares outstanding. Additionally, it has 6,514 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights is 80,486,497, while the total number of exercisable voting rights stands at 80,467,922. This disclosure aligns with French regulatory requirements set forth by the AMF to keep the market informed.
As of February 1, 2022, Innate Pharma SA reports a total of 79,543,377 ordinary shares outstanding. The company also has 6,514 preferred shares from 2016 and 7,581 preferred shares from 2017. The total theoretical voting rights amount to 80,301,217, while the exercisable voting rights stand at 80,282,642. This disclosure aligns with French regulations aimed at promoting transparency in share ownership and voting rights.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced the participation of its senior management team in two upcoming virtual investor conferences on February 16, 2022. These events are the Citi's 2022 Virtual Immuno-Oncology Summit and the SVB Leerink Virtual 11th Annual Global Healthcare Conference. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment, with a strong pipeline and collaborations with major biopharmaceutical companies such as Bristol-Myers Squibb and AstraZeneca.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
